Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy.

Autor: van Grootveld R; Leiden University Medical Center, Leiden, the Netherlands; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Electronic address: r.van_grootveld@lumc.nl., van der Beek MT; Leiden University Medical Center, Leiden, the Netherlands., Janssen NAF; Radboud University Medical Center, Nijmegen, the Netherlands; Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom., Ergün M; Radboud University Medical Center, Nijmegen, the Netherlands., van Dijk K; Amsterdam University Medical Center, Amsterdam, the Netherlands., Bethlehem C; Medical Center Leeuwarden, Leeuwarden, the Netherlands., Stads S; Ikazia, Rotterdam, the Netherlands., van Paassen J; Leiden University Medical Center, Leiden, the Netherlands., Heunks LMA; Amsterdam University Medical Center, Amsterdam, the Netherlands; Erasmus University Medical Center, Rotterdam, the Netherlands., Bouman CSC; Amsterdam University Medical Center, Amsterdam, the Netherlands., Reijers MHE; Radboud University Medical Center, Nijmegen, the Netherlands., Brüggeman RJ; Radboud University Medical Center, Nijmegen, the Netherlands., van de Veerdonk FL; Radboud University Medical Center, Nijmegen, the Netherlands., van Bree SHW; Gelderse Vallei Hospital, Ede, the Netherlands., van den Berg CHSB; University Medical Center Groningen, Groningen, the Netherlands., Kuindersma M; Gelre Hospitals, Apeldoorn, the Netherlands., Wauters J; University Hospitals Leuven, Leuven, Belgium., Beishuizen A; Medical Spectrum Twente, Enschede, the Netherlands., Verweij PE; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; Radboud University Medical Center, Nijmegen, the Netherlands., Schouten JA; Radboud University Medical Center, Nijmegen, the Netherlands.
Jazyk: angličtina
Zdroj: Journal of critical care [J Crit Care] 2023 Aug; Vol. 76, pp. 154272. Date of Electronic Publication: 2023 Feb 16.
DOI: 10.1016/j.jcrc.2023.154272
Abstrakt: Purpose: COVID-19 associated pulmonary aspergillosis (CAPA) is associated with increased morbidity and mortality in ICU patients. We investigated the incidence of, risk factors for and potential benefit of a pre-emptive screening strategy for CAPA in ICUs in the Netherlands/Belgium during immunosuppressive COVID-19 treatment.
Materials and Methods: A retrospective, observational, multicentre study was performed from September 2020-April 2021 including patients admitted to the ICU who had undergone diagnostics for CAPA. Patients were classified based on 2020 ECMM/ISHAM consensus criteria.
Results: CAPA was diagnosed in 295/1977 (14.9%) patients. Corticosteroids were administered to 97.1% of patients and interleukin-6 inhibitors (anti-IL-6) to 23.5%. EORTC/MSGERC host factors or treatment with anti-IL-6 with or without corticosteroids were not risk factors for CAPA. Ninety-day mortality was 65.3% (145/222) in patients with CAPA compared to 53.7% (176/328) without CAPA (p = 0.008). Median time from ICU admission to CAPA diagnosis was 12 days. Pre-emptive screening for CAPA was not associated with earlier diagnosis or reduced mortality compared to a reactive diagnostic strategy.
Conclusions: CAPA is an indicator of a protracted course of a COVID-19 infection. No benefit of pre-emptive screening was observed, but prospective studies comparing pre-defined strategies would be required to confirm this observation.
Competing Interests: Declaration of Competing Interest Paul Verweij: Institution contracted for research grant: F2G and Gilead Sciences; Honoraria for lectures paid to institution: F2G, Gilead Sciences, Pfizer; Participation on a Data Safety Monitoring Board or Advisory Board paid to institution: F2G, Mundipharma. Roger Brüggeman: Institution contracted for research grant: Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., Pfizer; Consulting fees paid to institution: Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., Mundipharma, Pfizer. Joost Wauters: Investigator-initiated grants: Gilead, MSD, Pfizer; Consulting fees: Investigator-initiated grants from Gilead, Pfizer; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Speakers fees from Gilead, Pfizer; Support for attending meetings and/or travel: travel grants from Gilead and Pfizer. No potential financial or non-financial competing interest was reported by any of the other authors.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: